Tin tức & Cập nhật

Chỉ hiển thị Multimedia
First-line rucaparib boosts PFS in ovarian cancer regardless of HRD status

First-line rucaparib boosts PFS in ovarian cancer regardless of HRD status

15 Sep 2022 bởiRoshini Claire Anthony

First-line rucaparib maintenance therapy extends progression-free survival (PFS) in patients with ovarian, fallopian tube, or primary peritoneal cancer, according to results of the phase III ATHENA-MONO trial presented at the ESMO Gynaecological Cancers Conference 2022.

15 Sep 2022
CNS metastasis worsens survival in endometrial cancer

CNS metastasis worsens survival in endometrial cancer

12 Sep 2022

Among patients with endometrial cancer (EC), central nervous system metastasis (CNSm) is strongly associated with poor prognoses and survival outcomes, a recent study has found.

12 Sep 2022